ImmunAdd has completed the manufacturing and pharmacology/toxicology studies required for the preclinical trials of its next-generation saponin adjuvant. Offering sustainable supply and lower toxicity, the adjuvant holds significant application value in the vaccine field. The company has been steadily expanding its business development (BD) team and is actively attending major international conferences to engage global pharmaceutical companies in licensing discussions, including the following events:

• March 30 – April 2, 2026 | World Vaccine Congress in Washington, D.C., USA, for product promotion.
• May 6 – 8, 2026 | International Symposium on Immunobiologicals in Brazil, where ImmunAdd delivered a presentation titled “Harnessing glycobiology to design novel vaccine adjuvants.”
• June 22 – 25, 2026 | BIO International Convention in San Diego, USA.
• July 16 – 19, 2026 | Exhibition at Hall 1, 4F, Taipei Nangang Exhibition Center, Taiwan. ImmunAdd’s booth is L321 — partners and investors are warmly welcome to visit.